HARBOUR BIOMED LAUNCHES NONA BIOSCIENCES’ "IDEAS TO IND" PRECLINICAL SOLUTIONS BUSINESS TO ACCELERATE GLOBAL BIOTHERAPEUTIC INNOVATION – QNT Press Release


CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 14, 2022 /PRNewswire/ — Harbor BioMed (HKEX: 02142) today announced the establishment of a wholly-owned subsidiary, Nona Biosciences, to provide next-generation antibody and biotherapeutic solutions to partners from discovery to IND. The new subsidiary will leverage Harbor BioMed’s technology platforms , including its Harbour Mice® and HBICE® for fully human antibody generation, and demonstrated expertise in discovery and development, along with an innovative business model to make these technologies broadly accessible to biotechnology and biopharma companies and academic institutions.

Nona Biosciences has wisely opened access to its industry-leading patented technology platform Harbour Mice® with a flexible business model, in order to remove platform barriers for partners and to enable the platform and technology to truly empower the discovery and development of next-generation innovative therapeutics worldwide. This new approach provides a significant new alternative to the company’s Harbour Mice® platform licensing.

“The biopharma industry is moving towards more complex, fully human biologic therapeutics, such as bi-specific antibodies and antibody drug conjugates, as well as cell therapies including CAR-T, CAR-NK and mRNA-based drugs,” said Dr. Jingsong WangFounder, Chairman and CEO of Harbour BioMed. “Nona Biosciences will capitalize on our strong track record in biologic discovery and …

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center